Therapeutic inhibition of HBsAg and HBV cccDNA through a novel phased combination treatment: glycine and interferon-α.

ABSTRACT:

Background

The elimination of HBV covalently closed circular DNA (cccDNA) remains a critical hurdle for chronic hepatitis B (CHB) management.

Objective

In this investigation, we examined the efficacy of glycine administration and its potential enhancement in interferon-α (IFN-α) antiviral efficacy to stimulate hepatocyte proliferation to mitigate cccDNA levels.

Design

The study cohort comprised 89 healthy individuals and 496 HBV-infected patients, with subgroups of 30 and 42 participants receiving randomised nucleos(t)ide analogue (NA) and PegIFN-α treatments, respectively. Glycine concentrations were quantified via liquid chromatography‒tandem mass spectrometry, and its diagnostic potential was assessed via receiver operating characteristic curve analysis. The therap

SUBMITTER: Lin C 

PROVIDER: S-EPMC12703313 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature